Reed - Lane Inc's sourcing strategy exhibits a high degree of concentration, with a significant portion of their imported pharmaceutical products originating from India. Between 2022 and 2026, Reed - Lane imported finished pharmaceutical formulations valued at $1.1 million from India, encompassing 35 shipments and 70 unique formulations. The top four products imported include Guaifenesin ($522K), Dextromethorphan ($228K), Ephedrine ($200K), and Pseudoephedrine ($200K), all within the respiratory and OTC therapeutic category. This concentration indicates a strategic focus on specific products and suppliers.
The primary supplier, DR.REDDY'S LABORATORIES LIMITED, accounted for 78.5% of the total import value, followed by DR REDDYS LABORATORIES LIMITED with 20.5%, and GLAND PHARMA LIMITED with 1.0%. This heavy reliance on a limited number of suppliers may pose risks related to supply chain disruptions, pricing volatility, and dependency on supplier performance. However, it also suggests a strategic choice to maintain strong, focused relationships with key suppliers to ensure product quality and consistency.
